A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (RENEW-Smk-1)
A Phase 2, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for Reduction in Risk of Relapse to Cigarette Smoking in Adults (RENEW-Smk-1)
Sponsor: Eli Lilly and Company
Listed as NCT07223840, this observational or N/A phase trial focuses on Smoking and remains actively recruiting participants. Sponsored by Eli Lilly and Company, it has been updated 5 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Apr 18, 2026 — Present [daily]
Recruiting
Phase: PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
First recorded
Nov 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period. .
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Beijing, China , Chengdu, China , Chongqing, China , Dallas, United States , DeLand, United States , Dearborn, United States , Hangzhou, China , Hollywood, United States , Houston, United States and 17 more locations